Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Clinical trial NCT04895722 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04895722
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-25
- Primary completion
- 2025-05-21
- Enrollment
- 302
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.